Expected time to complete this activity as designed: 15 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

The role of IDH1/2 inhibitors are established as treatments for relapsed/refractory (RR) AML, and the IDH1 inhibitor ivosidenib has recently been approved by the FDA for adults aged 75 years or older with newly diagnosed AML who have an IDH1 mutation as detected by an FDA-approved test or are ineligible for intensive induction chemotherapy. In this activity, Dr. Eytan Stein discusses the rationale for studying IDH1/2 inhibitors in both newly diagnosed AML and RR AML, including the clinical implications that come with these approvals.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify the therapeutic rationales for combining the IDH1 and IDH2 inhibitors with other agents, including hypomethylating agents
  • Summarize results from clinical trials investigating the role of IDH1/2 inhibitors in the frontline setting in patients unfit for standard therapy
  • Describe studies evaluating the addition of the IDH1/2 inhibitors, ivosidenib and enasidenib, to standard induction and consolidation chemotherapies in patients with AML who have IDH1/2 mutations

Agenda

Research Report: IDH Inhibitor-based Therapy in AML – Eytan M. Stein, MD

Instructions for Participation and Credit

This activity is eligible for credit through December 13, 2020. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Eytan M. Stein, MD
Assistant Professor
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Eytan Stein received his medical degree from Northwestern University in Chicago, where he also completed his internal medicine residency. He then completed his fellowships in medicine at Weill Cornell Medical College, and in medical oncology and hematology at Memorial Sloan Kettering. He is an Assistant Professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City.

Dr. Stein holds board certification from the American Board of Internal Medicine, American Board of Clinical Oncology, and the American Board of Hematology. He focuses his practice on the treatment of acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. His research interests include developing novel, early phase clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.

©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-19-030-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Eytan Stein has received honoraria related to formal advisory activities from Agios, Amgen Inc., Astellas Pharma US, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Genentech, Inc., Novartis AG, PTC Therapeutics, Seattle Genetics, Inc., and Syros Pharmaceuticals, Inc. He has received grant support related to research activities from Agios, Amgen, Bayer AG, BioTheryX, Inc., Celgene, and Syndax Pharmaceuticals, Inc. He also owns significant holdings in Auron Therapeutics.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.